Key Events This Week
13 Apr: Stock opens at Rs.1,652.00, marginally down amid broader market weakness
15 Apr: Sharp rebound with 2.70% gain to Rs.1,696.65, supported by heavy call option volumes
16 Apr: Decline of 0.21% to Rs.1,693.15 despite bullish call option interest; heavy put option activity emerges
17 Apr: Further dip of 1.06% to Rs.1,675.20 as bearish sentiment intensifies
Monday, 13 April: Market Opens Soft Amid Broader Weakness
Sun Pharmaceutical began the week at Rs.1,652.00, down 0.16% from the previous Friday’s close. This decline was in line with the broader market, as the Sensex fell 0.76% to 34,738.75. The stock’s volume of 1,67,681 shares indicated steady investor interest despite the cautious mood. The pharmaceutical sector was under pressure, reflecting global uncertainties and sector-specific concerns.
Wednesday, 15 April: Strong Rebound Fueled by Call Option Surge
The stock rebounded sharply on 15 April, gaining 2.70% to close at Rs.1,696.65, its highest level for the week. This rally coincided with a remarkable surge in call option activity, with 10,432 contracts traded at the ₹1,700 strike price expiring on 28 April 2026. The turnover for these contracts reached approximately ₹849.99 lakhs, signalling strong speculative interest or hedging strategies among investors anticipating a potential price recovery.
Despite this optimism in the derivatives market, the underlying stock price remained slightly below the ₹1,700 strike, suggesting cautious optimism. The Sensex outperformed with a 1.89% gain, closing at 35,394.87, indicating a broadly positive market environment that supported the stock’s advance.
While markets shift, this one's charging ahead! This Micro Cap from Aquaculture shows the strongest momentum signals in current conditions. Don't miss out on this ride!
- - Strongest current momentum
- - Market-cycle outperformer
- - Aquaculture sector strength
Thursday, 16 April: Divergent Signals as Put Options Surge Amid Price Decline
On 16 April, Sun Pharma’s stock price slipped 0.21% to Rs.1,693.15, underperforming the Sensex’s modest 0.26% gain. This decline occurred despite the ongoing heavy call option activity, highlighting a complex market sentiment. Notably, the stock also saw a significant increase in put option volumes, with 4,967 contracts traded at the ₹1,680 strike price, generating a turnover of approximately ₹485.9 lakhs.
The surge in put options indicates growing bearish positioning or hedging among investors, reflecting concerns about near-term downside risks. The open interest for these puts stood at 1,625 contracts, signalling sustained bearish bets as the 28 April expiry approaches.
Technical indicators reinforced this cautious outlook, with the stock trading below all major moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling a persistent downtrend. Delivery volumes declined by 2.38% to 26.29 lakh shares compared to the five-day average, suggesting waning investor conviction.
Friday, 17 April: Bearish Sentiment Weighs on Stock Despite Sensex Gains
The week closed with Sun Pharma retreating 1.06% to Rs.1,675.20, while the Sensex advanced 0.94% to 35,820.15. This divergence underscores the stock’s relative weakness amid a broadly positive market backdrop. The continued bearish pressure in the options market, combined with technical weakness and reduced delivery volumes, suggests that investors remain cautious about the stock’s near-term prospects despite its large-cap status and recent upgrade to a Buy rating.
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-04-13 | Rs.1,652.00 | -0.16% | 34,738.75 | -0.76% |
| 2026-04-15 | Rs.1,696.65 | +2.70% | 35,394.87 | +1.89% |
| 2026-04-16 | Rs.1,693.15 | -0.21% | 35,485.91 | +0.26% |
| 2026-04-17 | Rs.1,675.20 | -1.06% | 35,820.15 | +0.94% |
Thinking about Sun Pharmaceutical Industries Ltd? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this large-cap stock!
- - Real-time Verdict available
- - Financial health breakdown
- - Fair valuation calculated
Key Takeaways
Mixed Derivatives Signals: The week saw heavy call option activity at the ₹1,700 strike price, signalling bullish speculation or hedging, while simultaneous heavy put option volumes at ₹1,680 strike reflected bearish sentiment. This divergence indicates market indecision ahead of the 28 April expiry.
Technical Weakness Persists: Sun Pharma traded below all major moving averages throughout the week, suggesting a sustained downtrend despite intermittent price gains. Declining delivery volumes further point to reduced investor conviction.
Relative Underperformance: The stock’s 1.24% weekly gain lagged the Sensex’s 2.33% rise, highlighting cautious investor stance amid broader market optimism.
Fundamental Strength Remains: Despite near-term caution, Sun Pharma’s large market capitalisation of ₹4,03,460 crore and a Mojo Score of 72.0 with a Buy rating reflect solid fundamentals and potential for recovery.
Conclusion
Sun Pharmaceutical Industries Ltd experienced a week of mixed signals, with a modest 1.24% price gain overshadowed by contrasting derivatives market activity and technical weakness. The heavy call and put option volumes at closely spaced strike prices reveal a market grappling with uncertainty as expiry approaches. While the stock’s fundamentals remain robust, the technical downtrend and cautious investor participation suggest that volatility may persist in the near term. Investors should closely monitor option open interest and price action in the coming days to gauge the stock’s directional bias ahead of expiry.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
